Medopad raises $25 million to detect chronic diseases using AI and big data
Summary
By remotely monitoring patients, healthcare professionals can track side effects of drugs and dosage, for example, and avoid the travel time involved in meeting in person. Additionally, the Medopad app can be used to solicit tests for conditions such as Pulmonary Hypertension, a form of high blood pressure that can affect the arteries in the lungs and heart. As with most other industries, AI is increasingly infiltrating the healthcare realm, as medical researchers and professionals seek new ways to optimize treatments and bring drugs to market more quickly. Last year, Medopad snapped up U.S. rival Sherbit, which operated a similar business — leveraging personal data to uncover health insights through sensors, devices, and apps. Medopad was previously touted as a unicorn in the making by KPMG, and while it has yet to achieve that status, its latest funding round with such a high-profile strategic backer puts it on a strong trajectory.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
